China Biotech Services Holdings Limited (CH BIOTECH SER) reported no changes to its share capital structure for July 2026. The company closed the month with 975.73 million issued ordinary shares and no treasury shares, maintaining full compliance with the Hong Kong Exchange’s 25% minimum public-float requirement.

Key Equity Metrics (31 July 2026) • Authorised share capital: 2.00 billion ordinary shares at HKD 0.10 each, totalling HKD 200.00 million; unchanged month-on-month. • Issued shares outstanding: 975.73 million; no change during the month. • Treasury shares: Nil.

Convertible Bond Overhang Two USD-denominated convertible bond tranches remain outstanding, together carrying the right to be exchanged for up to 455.01 million new shares: 1. 2024 Convertible Bonds – Principal: USD 6.00 million – Conversion price: HKD 1.11 per share (adjusted 20 Feb 2026) – Maximum shares on full conversion: 42.43 million – Maturity: 27 Dec 2026

2. 2026 Convertible Bonds – Principal: USD 35.00 million – Conversion price: HKD 0.66 per share – Maximum shares on full conversion: 412.58 million – Maturity: 20 Feb 2030

If both instruments were fully converted, the issued share count could rise to approximately 1.43 billion, implying potential dilution of about 46.6% relative to the current base.

No share options, warrants, share buy-backs, or Hong Kong Depositary Receipts were reported for the period.

The company submitted the monthly return on 4 August 2026, with Executive Director Liu Xiaolin confirming compliance with all relevant regulatory and listing requirements.